3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
57
Thoracic
24
Gynecologic
24
Genitourinary
21
Head & Neck
20
Dermatologic
18
Breast
18
Other solid neoplasm
10
CNS
4
Sarcoma
3
Lymphoid
2
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
16
Leukemia, Lymphocytic, Chronic, B-Cell
8
Hematologic Neoplasms
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Myelodysplastic Syndromes
4
Recurrence
3
Lymphoma, Mantle-Cell
3
Lymphoma, Follicular
3
Lymphoma, B-Cell
3
Leukemia
3
Waldenstrom Macroglobulinemia
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Neoplasm, Residual
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Myeloid, Chronic-Phase
2
Hodgkin Disease
2
Colorectal Neoplasms
2
Burkitt Lymphoma
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thrombocytosis
1
Stomach Neoplasms
1
Interventions
Specimen Handling
2
Polymerase Chain Reaction
2
Magnetic Resonance Spectroscopy
2
Gene Expression Profiling
2
Counseling
2
Bupropion
2
vactosertib
1
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
sapanisertib
1
relatlimab
1
pertuzumab
1
pembrolizumab
1
palbociclib
1
osimertinib
1
omipalisib
1
larotrectinib
1
ipatasertib
1
fludarabine phosphate
1
erdafitinib
1
entinostat
1
defactinib
1
dabrafenib
1
copanlisib
1
capivasertib
1
binimetinib
1
aldesleukin
1
adavosertib
1
Zinc Oxide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
pembrolizumab
×
Other hematologic neoplasm
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled